Modulation of ovarian function by an oral contraceptive containing 30 μg ethinyl estradiol in combination with 2.00 mg dienogest

Contraception

Volumn 56, Issue 3, 1997, Pages 185-191

  Spona, J ^a,b,e   Feichtinger, W ^c   Kindermann, C ^c   Moore, C ^d   Mellinger, U ^d   Walter, F ^d   Graser T ^d  

^a UNIVERSITY OF VIENNA   (Austria)

^b LAB 19   (Austria)

^c Institute for Sterility Treatment   (Austria)

^d BAYER PHARMA AG   (Germany)

^e NONE   (Austria)

Author keywords

Dienogest; Follicle growth; Oral contraceptive

Indexed keywords

DIENOGEST; ESTRADIOL; ETHINYLESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE;

ADULT; ARTICLE; BREAKTHROUGH BLEEDING; CLINICAL TRIAL; DRUG MIXTURE; ECHOGRAPHY; ENDOMETRIUM; FEMALE; HEADACHE; HORMONE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; MASTALGIA; NAUSEA; ORAL DRUG ADMINISTRATION; OVARY; OVARY FOLLICLE; OVARY FUNCTION; OVULATION; SPOTTING; VERTIGO;

AUSTRIA; BIOLOGY; CLINICAL RESEARCH; CLINICAL TRIALS; CONTRACEPTION; CONTRACEPTIVE AGENTS, ESTROGEN--ADMINISTRACTION AND DOSAGE; CONTRACEPTIVE AGENTS, FEMALE--ADMINISTRACTION AND DOSAGE; CONTRACEPTIVE AGENTS, PROGESTIN--ADMINISTRACTION AND DOSAGE; CONTRACEPTIVE AGENTS--ADMINISTRACTION AND DOSAGE; CONTRACEPTIVE METHODS--ADMINISTRACTION AND DOSAGE; CONTRACEPTIVE MODE OF ACTION; DEVELOPED COUNTRIES; ENDOCRINE SYSTEM; ENDOMETRIAL EFFECTS; ENDOMETRIUM; ETHINYL ESTRADIOL--ADMINISTRACTION AND DOSAGE; EUROPE; FAMILY PLANNING; FOLLICLE STIMULATING HORMONE--ANALYSIS; GENITALIA; GENITALIA, FEMALE; GONADOTROPINS; GONADOTROPINS, PITUITARY; HORMONES; LUTEINIZING HORMONE--ANALYSIS; ORAL CONTRACEPTIVES, COMBINED--ADMINISTRACTION AND DOSAGE; ORAL CONTRACEPTIVES--ADMINISTRACTION AND DOSAGE; OVARIAN EFFECTS; OVARY; OVULATION SUPPRESSION; PHYSIOLOGY; RESEARCH METHODOLOGY; RESEARCH REPORT; UROGENITAL SYSTEM; UTERUS; WESTERN EUROPE;

ADULT; CONTRACEPTIVES, ORAL; ENDOMETRIUM; ESTRADIOL; ETHINYL ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; LUTEINIZING HORMONE; NANDROLONE; OVARIAN FOLLICLE; OVULATION; PROGESTERONE;

EID: 0030774954     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(97)00123-6     Document Type: Article

References (22)

1. Committee on Safety of Drugs. Combined oral contraceptives. A statement by the committee on Safety of Drugs. Br Med J 1970;1:231-2.
2. Jeffcoat TNA. RCOG statement on oral contraceptives (letter). Br Med J 1970;1:293.
3. Meade TW. Oral contraceptives, clotting factors and thrombosis. Am J Obstet Gynecol 1982;142:758-61.
4. Sabra A, Bonnar J. Haemostatic system changes induced by 50 μg and 30 μg oestrogen/progestin oral contraceptives. Modification of oestrogen effects by levonorgestrel. J Reprod Med 1983;28(suppl):85-91.
5. Daly L, Bonnar J. Comparative studies of 30 μg ethinyl estradiol combined with gestodene and desogestrel on blood coagulation, fibrinolysis, and platelets. Am J Obstet Gynecol 1990;163:430-7.
6. Bonnar J, Daly L, Carroll E. Blood coagulation with a combination pill containing gestodene and ethinyl estradiol. Int J Fertil 1987;32(suppl):21-8.
7. Bonnar J. Coagulation effects of oral contraception. Am J Obstet Gynecol 1987;157:1042-8.
8. Oettel M, Carol W, Elger W, et al. A 19-norprogestin without a 17α-ethinyl group. II: Dienogest from a pharmacodynamic point of view. Drugs of Today 1995;31: 517-36.
9. Oettel M, Bervoas-Martin B, Elger W, et al. A 19-norprogestin without a 17α-ethinyl group. I: Dienogest from a pharmacokinetic point of view. Drugs of Today 1995;31:499-516.
10. Moore C, Walter F, Klinger G, et al. Der Einfluss von Dienogest auf die Ovulation junger Frauen und auf weitere ausgewählte endokrinologische Parameter. In: Teichmann AT, ed. Dienogest-Präklinik und Klinik eines neuen Gestagens. New York: Walter de Gruyter, 1995:161-71.
11. Mall-Haefeli M, Werner-Zodrow I, Huber PR, et al. Oral contraception and ovarian function. In: Runnebaum B, Rabe T, Kiesel L, eds. Female Contraception. Berlin: Springer-Verlag, 1988:97-105.
12. Finlay IG, Scott MBG. Patterns of contraceptive pill-taking in an inner city practice. Br Med J 1986;293: 601-2.
13. Killick SR, Bancroft K, Oelbaum S, et al. Extending the pill-free interval during combined oral contraception. Adv Contracept 1990;6:33-40.
14. Morris SE, Groom GV, Cameron ED, et al. Studies on low-dose contraceptives: plasma hormone changes in relation to deliberate pill omission. Contraception 1979;10:61-9.
15. Fitzgerald C, Feichtinger W, Spona J, et al. Comparison of the effects of two monophasic low-dose oral contraceptives on the inhibition of ovulation. Adv Contracept 1994;10:5-18.
16. Spona J, Feichtinger W, Kindermann C, et al. Inhibition of ovulation by an oral contraceptive containing 100 μg levonorgestrel in combination with 20 μg ethinylestradiol. Contraception 1996;54:299-304.
17. Spona J, Elstein M, Feichtinger W, et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception 1996;54:71-7.
18. Van der Does J, Exalto N, Dieben T, Coelingh Bennink H. Ovarian activity suppression by two different low-dose triphasic oral contraceptives. Contraception 1995; 52:357-61.
19. Van der Vange N. Ovarian activity during low-dose oral contraceptives. In: Chamberlain G, ed. Contemporary Obstetrics and Gynecology. London: Butterworths, 1988:315-26.
20. Killick SR. Ovarian follicles during oral contraceptive cycles: their potential for ovulation. Fertil Steril 1989; 52:80-2.
21. Hamilton CJCM, Hoogland HJ. Longitudinal ultrasonographic study of ovarian suppressive activity of a low-dose triphasic oral contraceptive during correct and incorrect pill intake. Am J Obstet Gynecol 1989;161: 1159-62.
22. Moore C, Walter F, Mellinger U, Zahradnik HP. Multizentrische Studie zu kontrazeptiver Sicherheit, Zyklusbeeinflussung und Verträglichkeit von MP 2000 Mikropilleein Zwischenbericht. In: Teichmann AT, ed. Dienogest. Berlin-New York: de Gruyter, 1995:203-12.